Meeting
2024 ASCO Gastrointestinal Cancers Symposium
Survival impact of homologous recombination deficiency in veterans with cholangiocarcinoma including mutual exclusivity with pathogenic KRAS and TP53.
Authors
Colin P. Bergstrom
Stanford University Medical Center, Stanford, CA
Colin P. Bergstrom , Ethan Samuel Lin , Eric G. Mehlhaff , Dyan M. Lesnik , Noelle K. LoConte , Sam Joseph Lubner , Kristina A. Matkowskyj , Monica Arun Patel , Sean Ronnekleiv-Kelly , Nataliya Volodymyrivna Uboha , Megan Wachsmann , David H. Wang , Albert Y. Lin , Jeremy D. Kratz
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Track
Pancreatic Cancer,Hepatobiliary Cancer,Neuroendocrine/Carcinoid,Small Bowel Cancer
Sub Track
Tumor Biology, Biomarkers, and Pathology
Citation
J Clin Oncol 42, 2024 (suppl 3; abstr 546)
DOI
10.1200/JCO.2024.42.3_suppl.546
Abstract #
546
Poster Bd #
F13
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Detection of homologous recombination deficiency (HRD) in cell-free DNA (cfDNA) using an amplicon-based next-generation sequencing (NGS) assay.
First Author: Jonathan Poh
Poster
2023 ASCO Annual Meeting
The spectrum of homologous recombination deficiency in cervical cancer: Is it also a cervical issue?
First Author: Muhammad Danyal Ahsan
Poster
2021 ASCO Annual Meeting
Pan-cancer evaluation of homologous repair deficiency somatic mutations and response to first-line anti-neoplastic therapy.
First Author: Jessica A Lavery
Poster
2023 ASCO Annual Meeting
Targeting germline or somatic DNA repair defects (beyond BRCA) in pancreatic cancer with niraparib: A phase II study (NIRA-PANC).
First Author: Anup Kasi